Online inquiry

IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13098MR)

This product GTTS-WQ13098MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ACVRL1 gene. The antibody can be applied in Hepatocellular carcinoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000020.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 94
UniProt ID P37023
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13098MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14051MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ7299MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FPA-008
GTTS-WQ7906MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK-249320
GTTS-WQ8525MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Hu3F8
GTTS-WQ4944MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ9194MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMGN853
GTTS-WQ10734MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ12194MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-022
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW